Latest 2cureX News & Updates

See the latest news and media coverage for 2cureX. We track all announcements, press releases, and industry mentions in real time, all in one place.

Company icon
2cureX

Developer of 3D tumoroid drug sensitivity tests

2curex.com
Headquarters
København Ø, Denmark
Founded year
2006
Company type
Public company
Number of employees
10–50

Last updated

Latest news about 2cureX

In short: 2cureX expanded its precision oncology infrastructure, secured funding through a directed issue, and reported reduced losses for the first half of 2025.

Company announcements

2cureX

2cureX completes SEK 7.51M directed issue

The issue is fully subscribed with demand far exceeding allocation. It signals investor confidence in clinical utility and execution ahead of precision oncology advancements.

2cureX

2cureX publishes interim report for first half of 2025

The report shows a reduced loss of -1,951 KSEK, cash at 5,098 KSEK, and highlights strategy execution, partnerships, and AI integration. CEO outlines priorities including expansion and approvals.

2cureX

2cureX pursues strategic collaboration with PreComb Therapeutics

They signed a Letter of Intent to align organoid-based drug response testing platforms under Operation Twin Code. Executives express optimism about building an end-to-end precision oncology platform.

Unlock all announcements with a

Media coverage

FinanzNachrichten

2cureX AB: 2cureX AB is in the process of securing a strategic collaboration with PreComb Therapeutics AG.

PreComb Therapeutics AG based in Switzerland and 2cureX AB have signed a Letter of Intent (LOI) to explore a strategic alliance that could align the...

Unlock all articles with a

Never miss news about 2cureX

Track 2cureX and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Trending companies

Discover what's making headlines across other trending companies.